Skip to NavigationSkip to content

New therapy wins EMA orphan drug designation for ALS

Published on 09/08/16 at 09:11am

French pharma company AB Science has announced that the European Medicines Agency has granted orphan drug status to masitinib for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, through inhibiting a limited number of kinases. AB Science indicates its mode of action makes is a candidate in oncology, inflammatory disease and in certain diseases of the central nervous system. It has performed well in trials for the degenerative ALS, which causes muscles to decrease in size.

In ongoing Phase II/III trials, masitinib was used in combination with riluzole and showed significant benefits in an interim analysis compared to riluzole alone. There is, of yet, no cure for the disease but treatment riluzole can extend life by several months. It has already been approved in the EU.

AB Science has welcomed the EMA’s orphan drug designation, highlighting how stringently the EMA administers the designation, compared to the US FDA. To qualify, AB Science had to demonstrate significant benefits that could be derived from masitinib, as well as demonstrate its efficacy alongside riluzole. The drug has already been granted orphan status by the FDA.

Alain Moussy, CEO at AB Science, says: “The granting of this orphan drug status is one more positive milestone from EMA after acceptance of the filing for conditional marketing authorisation, still planned in September 2016.”

ALS recently gained much notoriety due to the ubiquitous Ice Bucket Challenge, which filled our social media timelines around two years ago. It raised well over $100 million for the ALS research. Recently, it emerged that some of the funding used helped researchers make new genetic discoveries, as to how the disease develops.

Sean Murray

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches